Search results for "Toni"

showing 10 items of 8001 documents

The unpleasantness of tonic pain is encoded by the insular cortex

2005

Objective: Muscle pain differs from skin pain with respect to quality, accuracy of localization, and unpleasantness. This study was conducted to identify the brain regions associated with the affective-motivational component of tonic skin and muscle pain. Methods: Forty healthy volunteers were investigated in three groups with different F-18 fluorodeoxyglucose PET activation scans. A verbal rating scale (VRS) was used to quantify pain intensity and unpleasantness. One group was investigated during painful infusion of an acidified phosphate buffer (pH 5.2) into either muscle or skin for 30 minutes. Muscle and skin infusions were adjusted to achieve pain intensity rating of VRS = 40. The seco…

AdultMaleTime FactorsEmotionsPainStimulationBuffersInsular cortexGyrus CinguliBrain mappingFunctional LateralityTonic (physiology)Fluorodeoxyglucose F18Reference ValuesmedicineHumansMuscle SkeletalPain MeasurementSkinCerebral CortexBrain MappingSensory stimulation therapyNociceptorsMiddle AgedMagnetic Resonance ImagingGlucosemedicine.anatomical_structureCerebral cortexPositron-Emission TomographyAnesthesiaAcute DiseaseChronic DiseaseNociceptorFemaleNeurology (clinical)PsychologyAcidsInsulaNeurology
researchProduct

Psychophysics, flare, and neurosecretory function in human pain models: capsaicin versus electrically evoked pain.

2007

Intradermal capsaicin injection (CAP) and electrical current stimulation (ES) are analyzed in respect to patterns and test-retest reliability of pain as well as sensory and neurosecretory changes. In 10 healthy subjects, 2 CAP (50 g) and 2 ES (5 to 30 mA) were applied to the volar forearm. The time period between 2 identical stimulations was about 4 months. Pain ratings, areas of mechanical hyperalgesia, and allodynia were assessed. The intensity of sensory changes was quantified by using quantitative sensory testing. Neurogenic flare was assessed by using laser Doppler imaging. Calcito- nin gene-related peptide (CGRP) release was quantified by dermal microdialysis in combination with an en…

AdultMaleTime FactorsSensory Receptor CellsCalcitonin Gene-Related PeptideModels NeurologicalPainStimulationSensory systemCalcitonin gene-related peptidechemistry.chemical_compoundmedicineNoxious stimulusLaser-Doppler FlowmetryPsychophysicsHumansPain MeasurementSkinNerve Fibers UnmyelinatedNeuronal Plasticitybusiness.industryNociceptorsMiddle AgedNeurosecretory SystemsElectric StimulationPeripheralAnesthesiology and Pain MedicineAllodyniaNeurologychemistryCapsaicinHyperalgesiaRegional Blood FlowAnesthesiaHyperalgesiaFemaleNeurology (clinical)medicine.symptomCapsaicinInflammation MediatorsbusinessThe journal of pain
researchProduct

Conventional and spectral power analysis of all-night sleep EEG after subchronic treatment with paroxetine in healthy male volunteers.

1998

Paroxetine is a selective and potent serotonin reuptake inhibitor with reported antidepressant properties. Since changes in the regular sleeping pattern were described as side effects under treatment with paroxetine, the impact of the drug on the sleep architecture is of major interest. The present study addressed the question of subchronic effects of paroxetine medication (30 mg/day) in eight healthy male volunteers in a double blind, placebo-controlled crossover-design. Conventional sleep EEG parameters and additionally computed spectral power analysis based on FFT of 20-s time epochs in the delta, theta, alpha, beta and gamma frequency range for different sleep stages after 4 weeks of tr…

AdultMaleTime FactorsSerotonin reuptake inhibitorSleep REMNon-rapid eye movement sleepDouble-Blind MethodReference ValuesmedicineHumansPharmacology (medical)Biological PsychiatrySlow-wave sleepPharmacologySleep StagesAnalysis of VarianceCross-Over StudiesElectroencephalographySleep in non-human animalsParoxetineCircadian RhythmPsychiatry and Mental healthParoxetineNeurologyAnesthesiaAntidepressantAntidepressive Agents Second-GenerationNeurology (clinical)Sleep onset latencyPsychologySleepSelective Serotonin Reuptake Inhibitorsmedicine.drugEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
researchProduct

Time Course of 5-HT2A Receptor Occupancy in the Human Brain after a Single Oral Dose of the Putative Antipsychotic Drug MDL 100,907 Measured by Posit…

1997

MDL 100,907 is a potent and selective antagonist of 5-HT2A serotonin receptors. Animals studies suggest that MDL 100,907 may behave as an atypical antipsychotic drug. Positron emission tomograph (PET) using [11C]NMSP as the radiotracer was used to define the time course of 5-HT2 receptor occupancy in the human frontal cerebral cortex after a single oral dose of MDL 100,907 (10 or 20 mg) in nine healthy subjects. After the baseline scan each subject was studied three times post dosing at various time points. 5-HT2 occupancies were in the range of 70 and 90% after each dose. While the occupancy remains in this range over 24 hours after 20 mg MDL 100,907, it decreases by about 20% at 24 hours …

AdultMaleTime Factorsmedicine.drug_classAtypical antipsychoticPharmacologyPiperidinesOral administrationmedicineHumansReceptor Serotonin 5-HT2ACarbon RadioisotopesPositron emissionDosing5-HT receptorPharmacologymedicine.diagnostic_testbusiness.industry5-HT2 receptorBrainHuman brainFluorobenzenesPsychiatry and Mental healthmedicine.anatomical_structureSpiperonePositron emission tomographyReceptors SerotoninFemaleSerotonin AntagonistsbusinessAntipsychotic AgentsTomography Emission-ComputedNeuropsychopharmacology
researchProduct

Testosterone and aggressiveness.

2003

Aggressiveness is an ancestral behavior common to all animal species. Its neurophysiological mechanisms are similar in all vertebrates. Males are generally more aggressive than females. In this review, aggressive behavior in rodents, monkeys, and man and the role of testosterone and brain serotonin levels have been considered. Interspecifi c aggressiveness in rats has been studied considering the mouse-killing behavior; the neonatal androgenization of females increases adult mousekilling as does the administration of testosterone in adults. Intraspecifi c aggressiveness was studied by putting two or more male rats (or mice) in the same cage; the condition of subjection or dominance is infl …

AdultMaleaggressiveness •testosterone • androgen • behavior • dominance • serotoninHaplorhiniSettore BIO/09 - FisiologiaRatsAggressionMiceSocial DominanceAnimalsHumansTestosteroneSports
researchProduct

Epimutation at human chromosome 14q32.2 in a boy with a upd(14)mat-like clinical phenotype.

2009

Recently, three reports described deletions and epimutations affecting the imprinted region at chromosome 14q32.2 in individuals with a phenotype typical for maternal uniparental disomy of chromosome 14 [upd(14)mat]. In this study, we describe another patient with upd(14)mat-like phenotype including low birth weight, neonatal feeding problems, muscular hypotonia, motor and developmental delay, small hands and feet, and truncal obesity. Conventional cytogenetic analyses, fluorescence in situ hybridization subtelomere screening, multiplex ligation-dependent probe amplification analysis of common microdeletion and microduplication syndromes, and methylation analysis of SNRPN all gave normal re…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesMolecular Sequence DataMothersBiologyMethylationPolymorphism Single NucleotideEpigenesis GeneticGenomic ImprintingIntergenic regionGeneticsmedicineHumansAbnormalities MultipleEpigeneticsChildGenetics (clinical)GeneticsChromosomes Human Pair 14Muscular hypotoniamedicine.diagnostic_testBase SequenceChromosomeUniparental DisomySubtelomerePhenotypeDifferentially methylated regionsPhenotypeMutationFemaleFluorescence in situ hybridizationClinical genetics
researchProduct

Effects of subchronic paroxetine administration on night-time endocrinological profiles in healthy male volunteers

2000

Abstract To evaluate the subchronic effects of paroxetine, a selective serotonin reuptake inhibitor, on nocturnal endocrinological profiles, eight healthy male volunteers with no personal or family history of a psychiatric or neurological disease were administered paroxetine (30 mg/day) or placebo in a double-blind cross-over design. Drugs were given as a single dose at 10:00 h for a period of 4 weeks each. Between days 21 and 28 of each treatment period, sleep EEG was registered for four consecutive nights from 23:00 to 07:00 h. During the last night, hormonal profiles for prolactin, growth hormone (GH), cortisol, corticotropin (ACTH), luteinizing hormone (LH), testosterone and melatonin w…

AdultMaleendocrine systemmedicine.medical_specialtyHydrocortisoneEndocrinology Diabetes and MetabolismSerotonin reuptake inhibitorPlaceboPlacebosMelatoninEndocrinologyAdrenocorticotropic HormoneDouble-Blind MethodInternal medicinemedicineHumansBiological PsychiatryMelatoninCross-Over StudiesHuman Growth HormoneEndocrine and Autonomic SystemsElectroencephalographyLuteinizing HormoneParoxetineHormonesProlactinCircadian RhythmProlactinParoxetinePsychiatry and Mental healthEndocrinologySleep onsetReuptake inhibitorPsychologyLuteinizing hormoneSelective Serotonin Reuptake Inhibitorshormones hormone substitutes and hormone antagonistsmedicine.drugPsychoneuroendocrinology
researchProduct

Early Results of Fissurectomy and Advancement Flap for Resistant Chronic Anal Fissure without Hypertonia of the Internal Anal Sphincter

2010

The aim of this study was to assess the efficacy of fissurectomy with skin advancement flap in healing chronic anal fissures without hypertonia of the internal anal sphincter. Twenty-six consecutive patients who failed healing after well-practiced topical medical therapy were enrolled. Anorectal manometry was performed preoperative and 6 months postoperatively. All patients were treated with fissurectomy and advancement flap through healthy skin tissue. All patients healed completely within 30 days from operation. The intensity and the duration of pain post-defecation was reduced significantly with respect to the preoperative values starting from the first defecation. One patient suffered …

AdultMalemedicine.medical_specialtyAdolescentFissurectomy Resistant Chronic Anal FissureAnal CanalSurgical FlapsInternal anal sphincterYoung AdultFissurectomy with skin advancement flapMuscle HypertoniaMuscle HypertoniamedicineHumansPostoperative PeriodProspective StudiesDefecationProspective cohort studyDigestive System Surgical ProceduresAnal fissureFissures without hypertoniabusiness.industryUrinary retentionAnorectal manometryFissurectomy with skin advancement flap Fissures without hypertonia Surgery.General MedicineMiddle AgedPlastic Surgery Proceduresmedicine.diseaseSurgerySettore MED/18 - Chirurgia GeneraleTreatment OutcomeChronic DiseaseDefecationHypertoniaSurgeryFemaleFissure in Anomedicine.symptombusinessFollow-Up StudiesThe American Surgeon
researchProduct

Melatonin Secretion and Increased Daytime Sleepiness in Childhood Craniopharyngioma Patients

2002

Craniopharyngioma is a rare dysontogenetic benign tumor. Patients frequently suffer from endocrine deficiencies, sleep disturbances, and obesity due to pituitary and hypothalamic lesions. A self-assessment daytime sleepiness questionnaire (German version of the Epworth Sleepiness Scale) was used to evaluate 79 patients with childhood craniopharyngioma. Because hypothalamic lesions may explain daytime sleepiness in craniopharyngioma patients, salivary melatonin and cortisol concentrations were examined in obese and nonobese craniopharyngioma patients (n = 79), patients with hypothalamic pilocytic astrocytoma (n = 19), and control subjects (n = 30). Using a general linear model procedure anal…

AdultMalemedicine.medical_specialtyAdolescentHydrocortisoneEndocrinology Diabetes and MetabolismClinical BiochemistryAstrocytomaBiochemistryMelatoninCraniopharyngiomaEndocrinologySurveys and QuestionnairesInternal medicinemedicineHumansPituitary NeoplasmsObesityChildSalivaMelatoninHydrocortisoneMorningSleep disorderbusiness.industryEpworth Sleepiness ScaleBiochemistry (medical)Childhood Craniopharyngiomamedicine.diseaseCraniopharyngiomaEndocrinologyChild PreschoolFemaleSleep StagesHypothalamic Neoplasmsmedicine.symptombusinessSomnolencemedicine.drugThe Journal of Clinical Endocrinology & Metabolism
researchProduct

Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depressi…

2003

OBJECTIVE Current clinical knowledge holds that antidepressants have a delayed onset of efficacy. However, the delayed onset hypothesis has been questioned recently by survival analytical approaches. We aimed to test whether early improvement under antidepressant treatment is a clinically useful predictor of later stable response and remission. METHOD We analyzed data from a randomized double-blind controlled trial with mirtazapine and paroxetine in patients with major depression (DSM-IV). Improvement was defined as a 17-item Hamilton Rating Scale for Depression (HAM-D-17) score reduction of > or = 20%. Stable response was defined as > or = 50% HAM-D-17 score reduction at week 4 and week 6,…

AdultMalemedicine.medical_specialtyAdolescentMirtazapineMirtazapineMianserinAntidepressive Agents TricyclicDrug Administration Schedulelaw.inventionRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineAmbulatory CareHumansPsychiatrySurvival analysisDepression (differential diagnoses)AgedPsychiatric Status Rating ScalesDepressive DisorderHamilton Rating Scale for DepressionMiddle AgedPrognosisParoxetineSurvival AnalysisClinical trialPsychiatry and Mental healthParoxetineTreatment OutcomeAntidepressantDrug Therapy CombinationFemalePsychologySelective Serotonin Reuptake Inhibitorsmedicine.drug
researchProduct